In this Science segment, we examine the European Medicines Agency's recent decision to recommend granting marketing authorization for the anti-Alzheimer's drug lecanemab. This follows an earlier rejection of its commercialization, citing concerns that the risks outweighed the benefits. So, what changed, and is this drug really the miracle treatment for Alzheimer's that some claim it to be?
